Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01057147 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea
A Phase 2 study, sponsored by Kubota Vision.
- Completed
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
NCT01057147: Completed Phase 2 study, sponsored by Kubota Vision.
NCT01057147 is a Phase 2 study that has completed, run by Kubota Vision. The registered enrollment target is 116 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01057147, a Phase 2 study, has completed, sponsored by Kubota Vision.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of 2% rebamipide compared to placebo in clearing of fluorescein staining of the central cornea in subjects with dry eye disease.
Interventions
- DRUG rebamipide 2% ophthalmic suspension
- DRUG placebo eye drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2010-02 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
What the finished NCT01057147 record still lists
NCT01057147 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% lower).
The record links to 0 conditions, and to 2 interventions - of which rebamipide 2% ophthalmic suspension is the first listed.
NCT01057147 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01057147 about?
NCT01057147 is a clinical study titled "Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea". The purpose of this study is to evaluate the safety and efficacy of 2% rebamipide compared to placebo in clearing of fluorescein staining of the central cornea in subjects with dry eye disease.
What is the current status of trial NCT01057147?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2010-02. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01057147?
The interventions under investigation include: rebamipide 2% ophthalmic suspension (DRUG), placebo eye drops (DRUG).
Who is sponsoring clinical trial NCT01057147?
This trial is sponsored by Kubota Vision, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01057147's enrollment target sits among peer trials
116 623rd of 2000 higher than 1,375 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia